Author

Palle Bekker Jeppesen

SAFETY AND EFFICACY OF APRAGLUTIDE IN PATIENTS WITH SHORT BOWEL SYNDROME: AN OPEN-LABEL PHASE 2 METABOLIC BALANCE TRIAL
SAFETY AND EFFICACY OF APRAGLUTIDE IN PATIENTS WITH SHORT BOWEL SYNDROME: AN OPEN-LABEL PHASE 2 METABOLIC BALANCE TRIAL

Palle Bekker Jeppesen  et al.

SAFETY AND EFFICACY OF APRAGLUTIDE IN PATIENTS WITH SHORT BOWEL SYNDROME INTESTINAL FAILURE: A DOUBLE-BLIND, CROSSOVER, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL
SAFETY AND EFFICACY OF APRAGLUTIDE IN PATIENTS WITH SHORT BOWEL SYNDROME INTESTINAL FAILURE: A DOUBLE-BLIND, CROSSOVER, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL

Palle Bekker Jeppesen  et al.

THE LONG-ACTING GLP-2 ANALOG APRAGLUTIDE PROVIDES CLINICAL BENEFIT FOR PATIENTS WITH SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE AND COLON IN CONTINUITY AT 52 WEEKS
THE LONG-ACTING GLP-2 ANALOG APRAGLUTIDE PROVIDES CLINICAL BENEFIT FOR PATIENTS WITH SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE AND COLON IN CONTINUITY AT 52 WEEKS

Palle Bekker Jeppesen  et al.

ESPEN guidelines on chronic intestinal failure in adults
ESPEN guidelines on chronic intestinal failure in adults

Palle Bekker Jeppesen  et al.

SODIUM DEPLETION AND SECONDARY HYPERALDOSTERONISM IN OUTPATIENTS WITH AN ILEOSTOMY: A CROSS-SECTIONAL STUDY
SODIUM DEPLETION AND SECONDARY HYPERALDOSTERONISM IN OUTPATIENTS WITH AN ILEOSTOMY: A CROSS-SECTIONAL STUDY

Palle Bekker Jeppesen  et al.

APRAGLUTIDE, A NOVEL LONG-ACTING GLP-2 ANALOG, IMPROVES WET WEIGHT ABSORPTION IN SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF) AND COLON-IN-CONTINUITY (CIC)
APRAGLUTIDE, A NOVEL LONG-ACTING GLP-2 ANALOG, IMPROVES WET WEIGHT ABSORPTION IN SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE (SBS-IF) AND COLON-IN-CONTINUITY (CIC)

Palle Bekker Jeppesen  et al.

TRANSFERABILITY OF METABOLIC BALANCE STUDIES IN SHORT BOWEL SYNDROME: ANALYSIS OF DRY MATTER AND ENERGY CONTENTS
TRANSFERABILITY OF METABOLIC BALANCE STUDIES IN SHORT BOWEL SYNDROME: ANALYSIS OF DRY MATTER AND ENERGY CONTENTS

Palle Bekker Jeppesen  et al.

GLEPAGLUTIDE, A NOVEL LONG-ACTING GLP-2 ANALOGUE, EXPOSURE DOES NOT CORRELATE WITH HEPATIC INDOCYANINE GREEN CLEARANCE
GLEPAGLUTIDE, A NOVEL LONG-ACTING GLP-2 ANALOGUE, EXPOSURE DOES NOT CORRELATE WITH HEPATIC INDOCYANINE GREEN CLEARANCE

Palle Bekker Jeppesen  et al.

EARLY RESPONSE TO GLEPAGLUTIDE, A NOVEL LONG-ACTING GLP-2 ANALOG, IN SHORT BOWEL SYNDROME PATIENTS WITH INTESTINAL FAILURE: RESULTS OF 24-WEEK PHASE 3 TRIAL
EARLY RESPONSE TO GLEPAGLUTIDE, A NOVEL LONG-ACTING GLP-2 ANALOG, IN SHORT BOWEL SYNDROME PATIENTS WITH INTESTINAL FAILURE: RESULTS OF 24-WEEK PHASE 3 TRIAL

Palle Bekker Jeppesen  et al.

Item 1 - 9 / 9
1